Use of ivabradine for angina pectoris caused by coronary artery disease does not seem to improve patient outcomes and may even be harmful, as it increases the risk of adverse events such as atrial fibrillation, according to the results of a systematic review and meta-analysis.
Mirabegron appears to be a safe add-on therapy in men receiving tamsulosin for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia, according to data from the phase IV PLUS study.
An academic, primary care clinic has significantly and sustainably reduced the inappropriate use of proton pump inhibitors (PPI) to 30 percent from the baseline rates of 80 percent, surpassing its goal within 12 months, a recent study has shown.
N-acetylcysteine provides a protective effect on chemotherapy-induced neuropathy by reducing its incidence and delaying its occurrence in patients with gastric or colorectal cancers, a study has shown.
Direct-acting oral anticoagulants (DOACs) have fewer drug–drug interactions (DDIs) than warfarin, but the severity of interaction varies between DOACs, a recent study has found. In addition, some anticoagulant-drug interactions correlate with bleeding or venous thromboembolism (VTE).
Age >65 years and metastatic cancer are significantly associated with cisplatin-induced nephrotoxicities, a recent study has found. An association also exists between cumulative dose and nephrotoxicity or digestive toxicity.
Repeated doses of diclofenac etalhyaluronate (DF-HA) yield improvements in knee osteoarthritis (OA) pain without major safety signals, with the effect occurring as early as week 1, according to the results of a phase II trial.
Use of liraglutide in obese patients with type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD) receiving metformin yields favourable effects on liver fat content and abdominal adiposity, with additional benefits of inducing weight loss and improving liver function, as compared with insulin glargine and placebo, a study reports.
Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.